GET DAILY SIGNALSAllarity Therapeutics (ALLR) Climbs +9% as Pipeline and Lab Strategy Take Shape
Key Takeaways
- ALLR shares have moved modestly higher over the trailing 30 days, gaining roughly 9% from the low-$0.80s to near $0.95 as of the latest close, though the stock remains below $1 and well off its 52-week high of $1.84.
- Allarity Therapeutics is a clinical-stage precision-medicine biotech advancing stenoparib, a dual PARP1/2 inhibitor, through Phase 2 development in advanced ovarian cancer.
- The company recently reported third-quarter 2026 results, ending the period with $24.1 million in cash and restricted cash, and issued guidance for positive fourth-quarter earnings per share.
- Allarity secured its first commercial agreement under a newly established CLIA-certified laboratory services strategy, an early step toward recurring revenue beyond its core drug pipeline.
- Key investor considerations include the early-stage nature of the pipeline, clinical trial readouts, and financing or dilution risk common to micro-cap biotechs.
- Readers can find additional detail on Price Targets, Earnings, and Forecast on dedicated pages.
- Explore Trending AI Robots to see how algorithmic trading strategies are tracking stocks like ALLR.
Current Market Snapshot
From what I see, ALLR has traded in a relatively contained range over the past month, with its share price holding in the high-$0.80s to low-$1.00 band. The latest available close sits near $0.95, roughly 9% above levels recorded about 30 days earlier. On a longer horizon, the picture is more subdued: the stock has declined about 30% over the trailing three months and remains well below its 52-week high of $1.84, reflecting the volatility typical of early-stage biotechnology names.
With a market capitalization of approximately $15 million and a 52-week range spanning roughly $0.77 to $1.84, ALLR carries a small-cap, high-beta profile. Investor attention has centered less on broad market direction and more on company-specific developments, including its lead oncology asset, laboratory services strategy, and balance-sheet positioning. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Allarity Therapeutics (ALLR) Business Overview and Competitive Position
Allarity Therapeutics, Inc. is a clinical-stage precision-medicine pharmaceutical company headquartered in Tarpon Springs, Florida, with operations in the United States and Denmark. The company develops personalized anti-cancer therapies using its proprietary Drug Response Predictor (DRP) technology, which is designed to identify gene-expression signatures that predict whether a patient's cancer is likely to respond to a specific drug.
Its lead candidate is stenoparib, an orally available dual inhibitor of PARP1/2 that is in Phase 2 clinical development for patients with advanced and recurrent ovarian cancer. The company is also evaluating stenoparib in combination with temozolomide for relapsed small-cell lung cancer, alongside a companion diagnostic (stenoparib-DRP) intended to guide patient selection. This precision-oncology approach — pairing a therapeutic with a companion diagnostic — is central to Allarity's differentiation within the competitive PARP-inhibitor landscape.
Recent Developments Driving ALLR
Several verified company updates have shaped investor sentiment in recent weeks. In mid-November, Allarity reported third-quarter 2026 results, disclosing $24.1 million in cash and restricted cash at quarter-end and providing full-year 2026 financial guidance that includes expectations for positive fourth-quarter earnings between $0.01 and $0.04 per share.
Earlier, the company announced its first revenue-generating contract under a newly established CLIA-certified laboratory services strategy. The agreement, supporting a European biotechnology company's precision-oncology predictive development work, marks an initial step toward complementary, recurring revenue streams beyond the drug pipeline. Allarity also reported progress on its DRP technology, an expanded in-house laboratory capability covering proteomics and cell-line research, and the grant of a Japanese patent for its stenoparib DRP companion diagnostic, reinforcing its intellectual-property position. I’m watching this closely because these steps could support longer-term stability.
2026 Outlook and What Investors Should Watch
Looking ahead, the most consequential catalysts for Allarity revolve around clinical execution and early commercialization. Phase 2 data for stenoparib in advanced ovarian cancer and any updates on the stenoparib-plus-temozolomide program remain central to the investment thesis, as do regulatory milestones following the Fast Track designation previously granted to the lead asset.
On the financial side, investors are likely to monitor whether the company can build on its first CLIA laboratory agreement, sustain its cash position, and deliver on its stated expectation for positive fourth-quarter earnings. As with many micro-cap biotechs, financing activity and potential share dilution remain key risks, alongside clinical, regulatory, and competitive pressures within the PARP-inhibitor space. Continued progress on the DRP companion-diagnostic platform and additional patent grants could further validate the company's precision-medicine strategy.
Exploring AI Tools for Stock Analysis
In my view, incorporating data-driven resources can complement traditional research when evaluating names like ALLR. I recently reviewed signals from Tickeron’s AI Trading Bots to see how automated strategies have performed around similar micro-cap biotechs. These tools help surface patterns across thousands of tickers without replacing personal due diligence, and they offer a practical way to cross-check ideas generated from company filings and news.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
ALLR's Stochastic Oscillator stays in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on ALLR as a result. In 55 of 67 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for ALLR just turned positive on October 21, 2026. Looking at past instances where ALLR's MACD turned positive, the stock continued to rise in 24 of 31 cases over the following month. The odds of a continued upward trend are 77%.
Following a +29.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLR advanced for three days, in 144 of 176 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 48 of 61 cases where ALLR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for ALLR moved out of overbought territory on November 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 14 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
ALLR moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for ALLR moved below the 200-day moving average on October 12, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ALLR broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. ALLR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.361) is normal, around the industry mean (3.498). P/E Ratio (-1.227) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (52.632) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement